Wells Fargo Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $60
Wells Fargo analyst Mohit Bansal maintains Bristol-Myers Squibb (NYSE:BMY) with a Equal-Weight and lowers the price target from $65 to $60.
Share
Why It Matters
A big bank analyst thinks Bristol-Myers stock is okay, not great. They lowered how high they think the price could go.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.